Northeast Financial Consultants’s Precigen PGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-164,209
Closed -$174K 318
2023
Q1
$174K Hold
164,209
0.01% 301
2022
Q4
$250K Hold
164,209
0.02% 267
2022
Q3
$348K Sell
164,209
-50,000
-23% -$105K 0.03% 241
2022
Q2
$287K Hold
214,209
0.02% 264
2022
Q1
$452K Hold
214,209
0.03% 242
2021
Q4
$795K Hold
214,209
0.05% 178
2021
Q3
$1.07M Hold
214,209
0.07% 155
2021
Q2
$1.4M Buy
214,209
+165,454
+339% +$1.16M 0.09% 129
2021
Q1
$336K Hold
48,755
0.03% 258
2020
Q4
$497K Hold
48,755
0.04% 197
2020
Q3
$171K Hold
48,755
0.02% 283
2020
Q2
$243K Buy
48,755
+7,874
+19% +$26.8K 0.02% 245
2020
Q1
$139K Hold
40,881
0.02% 252
2019
Q4
$224K Sell
40,881
-594
-1% -$3.34K 0.02% 273
2019
Q3
$237K Hold
41,475
0.02% 274
2019
Q2
$318K Hold
41,475
0.03% 233
2019
Q1
$218K Hold
41,475
0.02% 284
2018
Q4
$271K Buy
41,475
+594
+1% +$6.66K 0.04% 137
2018
Q3
$703K Buy
+40,881
New +$608K 0.19% 66
2015
Q3
Sell
-5,045
Closed -$244K 148
2015
Q2
$244K Sell
5,045
-187
-4% -$7.88K 0.11% 129
2015
Q1
$227K Buy
+5,232
New +$188K 0.1% 126

Other funds holding PGEN

Northeast Financial Consultants's PGEN Position: Q2 2023 in Review

Northeast Financial Consultants sold out of Precigen (PGEN) in Q2 2023, closing a stake of 164,209 shares — an estimated $174K sold.

Northeast Financial Consultants first reported a position in PGEN in Q1 2015 and held it in 21 quarters. The position peaked at $1.4M in Q2 2021. 138 funds tracked by Wall St. Rank hold PGEN as of Q2 2023.

  • Northeast Financial Consultants reported no remaining Precigen position as of Q2 2023 after selling out during the quarter.
  • Northeast Financial Consultants sold 164,209 Precigen shares in Q2 2023, an estimated $174K.
  • Northeast Financial Consultants first reported a position in Precigen in Q1 2015 and held it in 21 quarters.
  • Northeast Financial Consultants's Precigen position peaked at $1.4M in Q2 2021.
  • 138 funds tracked by Wall St. Rank held Precigen as of Q2 2023.

Based on Northeast Financial Consultants's 13F filing for Q2 2023, filed 8 Aug 2023.